tbuckley/cabot-search huggingface dataset:
Respiratory Syncytial Virus Infection Outbreak and Successful Treatment with IVIG and Oral Ribavirin among Pediatric Patients with Oncologic Diseases and/or BMT.
Authors: Sema S. Anak, Didem Atay, Mesut Garipardic, Beril Ozalp, Diana Yani, Leyla Agaaoglu, Gulyuz Ozturk, Aysegul Unuvar, Zeynep Karakas, Omer Devecioglu
Journal: Blood (2006)
Hereditary Hemorrhagic Telangiectasia (Osler-Weber-Rendu Syndrome) with Transfusion Requirement. Effect of Danazol in 18 Patients with Long Follow-Up.
Authors: Jose Fernandez, Dardo Riveros, Guy Garay, Reinaldo Campestri, Gonzalo Garate, Beatriz Grand, Juan Dupont, Roberto Cacchione
Journal: Blood (2004)
Hospital transmitted<i>Candida auris</i>infections confirmed in the US
Authors: Michael McCarthy
Journal: BMJ (2016)

An invasive fungus that is often resistant to antifungal agents and associated with high mortality was being transmitted in US health facilities, the US Centers for Disease Control and Prevention (CDC) said in a report released on 4 November.1

The fungus, Candida auris , was first described in Japan in 2009.2 Since then it has been reported in several other countries, including Colombia, India, Israel, Kenya, Kuwait, Pakistan, South Africa, South Korea, Venezuela, and the UK. To determine whether C auris …
Analysis of Common Single Nucleotide Polymorphisms in MDR1 Gene in Patients with Multiple Myeloma.
Authors: Krzysztof Jamroziak, Ewa Balcerczak, Piotr Smolewski, Sylwester Piaskowski, Barbara Cebula, Mariusz Panczyk, Agnieszka Janus, Marek Mirowski, Tadeusz Robak
Journal: Blood (2004)
Time to Nadir Peripheral White Blood Cell Count (WBC) and Absolute WBC Nadir Value Following Induction Chemotherapy in Older Adults with Acute Myeloid Leukemia (AML) Predicts Survival.
Authors: Hyo Sook Han, Lisa Rybicki, Matt Kalaycio, Stacey Brown, Anjali Advani, Brad Pohlman, Ronald Sobecks, Mikkael Sekeres
Journal: Blood (2004)
PWE-057 Does Restriction of Gluten-Free Prescription Foods Affect People with Coeliac Disease?
Authors: M Kurien, WL White, N Trott, DS Sanders
Journal: Gut (2016)

<h3>Introduction</h3> A gluten-free diet (GFD) is the mainstay of treatment for coeliac disease (CD). Since the late 1960 s prescriptions for gluten-free foods have been widely available, helping CD patients maintain dietary adherence and reduce complications. In Scotland and Wales GF foods are widely prescribed in accordance with the National Prescribing Guidelines. In England however, whilst the vast majority of Clinical Commissioning Groups (CCGs) are following this guidance some have chosen not to. This has lead to the reduction or removal of prescriptions in certain parts of England. This cohort study examines the influence restriction or removal of GF prescriptions may have on CD patients. <h3>Methods</h3> Between September and October 2015, CD patients and carers of CD patients were approached from 4 differing CCG areas (North Norfolk, West Suffolk, Oxfordshire, Vale of York). These CCG areas were specifically selected as areas where CCGs had either restricted or removed GF prescriptions. All participants were asked to complete an online questionnaire, with information requested pertaining to prescriptions, availability of GF foods, costs incurred and what influence changes to prescriptions have had on health. Findings from this work were then compared to a previous study assessing primary care trusts, undertaken in 2013 (n = 1000).<sup>1</sup> Statistical analyses was performed using SPSS version 20.0, with X<sup>2</sup> statistics used to compare categorical data. <h3>Results</h3> 25.0% (894/3586) of invited individuals completed the online questionnaire (632 F: 262 M, mean age of 59.2 years). Compared to the 2013 cohort, there was a significant reduction in the number of patients receiving gluten-free prescriptions (63% versus 70%, p &lt; 0.001). Nearly 60% (514/894) of respondents felt less supported in the management of their CD due to changes in their prescription, with only 37.2% (333/894) currently meeting national guideline standards by having an annual follow-up appointment. Although only 6.7% (n = 60) felt that the prescription changes had directly affected their health, costs incurred to them had increased (median weekly cost = £8.62). Although not statistically significant, the greatest detriment to health was noted in those having complete removal of their GF prescriptions (North Norfolk 9.1%). <h3>Conclusion</h3> Although this study is confined to only 2% (4/209) of all CCGs in England, it raises concerns as to how the restriction and removal of gluten-free prescriptions can affect patients with CD. Given these findings, further work should now aim to establish whether prescription restriction is a false economy, as detriment may ensue due to poor dietary adherence and the development of serious long-term complications. <h3>Reference</h3> 1 The impact of the restrictions to gluten-free prescription foods on people with Coeliac Disease. <i>BSNA</i>. 2013. <h3>Disclosure of Interest</h3> None Declared
SAT0645-HPR Results of A Goal Management Intervention for Patients with Polyarthritis with Mild Depressive Symptoms
Authors: R. Arends, C. Bode, E. Taal, M. van de Laar
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> Persisting disease symptoms can threaten attainment of personal important goals for patients with polyarthritis, resulting in elevated levels of depression and anxiety<sup>1</sup>. Interventions that provide patients with the skills and techniques to live with and manage their disease in daily life are essential, as people have to manage a chronic disease most of the time outside of the health-care system. For this purpose participants practice four goal management competencies (goal maintenance, goal adjustment, goal disengagement and goal re-engagement) and the flexible use of these strategies during the self-management intervention "Right on Target". <h3>Objectives</h3> The purpose of this study was to establish whether an intervention aimed at increasing goal management capacities is effective in decreasing symptoms of depression and increasing adaptation in patients with polyarthritis with elevated levels of depressive symptoms. <h3>Methods</h3> In total, 85 persons with a diagnosis of polyarthritis and elevated levels of depression received the group-based goal management intervention <i>Right on Target</i> with measurements at baseline, post-intervention (after 2 months) and follow-up (6 months). A quasi-experimental design was applied in which the reference group consisted of 151 participants of a previously conducted observational study selected according to the inclusion criteria for the intervention group. Primary outcome was depression, secondary outcomes anxiety, purpose in life, positive affect and satisfaction with participation. Mediating variables were goal management strategies and arthritis self-efficacy. Linear mixed model procedure was applied to evaluate changes in outcomes. Proportions showing clinically relevant changes and possible mediators were analyzed. <h3>Results</h3> No improvement was found for depressive symptoms. Positive affect significantly improved in the intervention group mediated by an increase in goal adjustment. No changes were found for the other secondary outcomes, while goal maintenance decreased and self-efficacy for other symptoms than pain increased in the intervention group. <h3>Conclusions</h3> This study indicates the value of improving the management of personal threatened goals of people with polyarthritis and showed that especially facilitating goal adjustment and downgrading goal tenacity are potentially helpful. While more research is needed, the present study provides a small but promising direction towards greater wellbeing for patients with polyarthritis. <h3>References</h3> Arends RY, Bode C, Taal, E &amp; van de Laar MAFJ. The longitudinal relation between patterns of goal management and psychological health in people with arthritis: The need for adaptive flexibility. BJHP, 2016, DOI:10.1111/bjhp.12182 <h3>Disclosure of Interest</h3> None declared
FRI0336 Hypocomplementemia in Systemic Lupus Erythematosus; Establishing The Importance of Low C3 and C4 in A Longitudinal Cohort: Table 1
Authors: L. Durcan, W. Fu, M. Petri
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> Despite inclusion in systemic lupus erythematosus (SLE) disease activity indices and classification criteria, the relationship between hypocomplementemia, disease manifestations and cumulative organ damage has not been systematically investigated. It is also unknown whether there is a particular disease phenotype associated with chronic, unresolving hypocomplementemia. <h3>Objectives</h3> To evaluate SLE patients with a history of hypocomplementemia, to establish the relationship between clinical manifestations and organ damage. To compare low C3 to low C4 and establish relative importance for manifestations and damage parameters. To assess SLE patients with persistent hypocomplementemia to ascertain whether these patients have unique clinical characteristics. <h3>Methods</h3> As part of a lupus cohort, C3 and C4 were measured quarterly. Using univariate and multivariate methods, those with and without a history of low C3, low C4 and both were compared and an odds ratio calculated and compared using generalized linear hypothesis testing. We then considered those who had persistent hypocomplementemia (i.e. complement never normalized, on a minimum of 3 evaluations) and compared them to patients with a similar number of assessments. <h3>Results</h3> 2399 patients were included in the analysis; 47% had a history of low C4 and low C3 in 55%. Persistently low C3 was found in 83 (4.0%) and C4 in 65 (3.2%). A history of low C3 associated strongly with nephritis and with renal damage parameters. Low C4, in isolation, associated only with false positive RPR and the presence of arthritis. With unresolving hypocomplementemia (Table 1), strong associations were demonstrated between low C3, low C4 and both in combination and hematologic, serologic and antiphospholipid-related parameters. No associations were found for cutaneous disease. Persistently low C3 associated with nephritis. <h3>Conclusions</h3> A history of, and chronically low C3 associates uniquely with renal disease whilst a history of low C4, associated only with arthritis and a false positive RPR. Persistent hypocomplementemia associated strongly with other hematological and serological abnormalities. While a history of low C4 was not strongly associated with other disease activity parameters, chronically low C4 appears to be a more important marker. <h3>Disclosure of Interest</h3> None declared
An Integrative Tinnitus Model Based on Sensory Precision
Authors: William Sedley, Karl J. Friston, Phillip E. Gander, Sukhbinder Kumar, Timothy D. Griffiths
Journal: Trends in Neurosciences (2016)

Tinnitus is a common disorder that often complicates hearing loss. Its mechanisms are incompletely understood. Current theories proposing pathophysiology from the ear to the cortex cannot individually - or collectively - explain the range of experimental evidence available. We propose a new framework, based on predictive coding, in which spontaneous activity in the subcortical auditory pathway constitutes a 'tinnitus precursor' which is normally ignored as imprecise evidence against the prevailing percept of 'silence'. Extant models feature as contributory mechanisms acting to increase either the intensity of the precursor or its precision. If precision (i.e., postsynaptic gain) rises sufficiently then tinnitus is perceived. Perpetuation arises through focused attention, which further increases the precision of the precursor, and resetting of the default prediction to expect tinnitus.
AB1113-HPR Description of The Spare Time Utilization and Relationship between Functionality and Disease Activity in A Colombian Rheumatoid Arthritis Cohort
Authors: E. Rangel, L. Villarreal, P. Santos-Moreno, N. Palacio, C. Castro, D. Buitrago-Garcia
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> Spare time utilization is defined as delectable and non-remunerated activities that a person realizes through its vital cycle. In rheumatoid arthritis (RA) patients this activities might be altered by multiple causes as functional deterioration, psychological problems and social exclusion. <h3>Objectives</h3> The aim of this study is to describe the spare time activities and possible relationship with disease activity and functionality of a RA patient9s cohort. <h3>Methods</h3> A descriptive cross sectional study was realized. A revision of medical records of a cohort of RA patients was performed, including occupational therapy records. For all patients DAS28, HAQ, clinical evaluation and interests check list were made. Percentages, averages and Pearson9s statistics were used for clinical and occupational variables. <h3>Results</h3> Total sample of patients was 1298, 1048 (80%) were women and 250 (19%) were men. Patients had a DAS28 2.6 in average ± 1.1; mean age was 55.1 ± 8.8 years; 846 (65%) were in remission, 205 (16%) were in low disease activity, 208 (16%) in moderate disease activity and 42 in severe disease activity (3%). Regarding education, 6% were illiterate, 44% had elementary school, 33% high school, 8% had a technical degree and only 7% had college level. In the spare time activities the most frequent were: mixed activities 26% housekeeping 24%, and intellectual activities 15% and handcrafting activities 12%. It was not established correlation between spare time use and disease activity or functionality. <h3>Conclusions</h3> Even we did not find a statically correlation between practicing spare activities or not practice and the disease activity, we found that practicing sports improves in men DAS score. Most patients in this cohort prefer mixed activities as their main spare time activity, and other main frequent activities were handcrafting or home activities; perhaps it9s important to maintain in this cohort low activity disease and make more studies about this topic because study suggests that male who did only academic activities had more active disease. <h3>Disclosure of Interest</h3> None declared
Around 70% of Japanese CML Patients Could Stop Imatinib According to a-STIM Criteria: The JALSG-STIM213 Study
Authors: Naoto Takahashi, Tetsuzo Tauchi, Kunio Kitamura, Koichi Miyamura, Yoshio Saburi, Yasuhiko Miyata, Yoshihiro Hatta, Fumihiko Kimura, Satoru Takada, Tetsuya Fukuda, Katsumichi Fujimaki, Maho Ishikawa, Itaru Matsumura, Noriko Usui, Kensuke Usuki, Yukio Kobayashi, Tomoki Naoe
Journal: Blood (2015)
Phenome‐Wide Association Study of Autoantibodies to Citrullinated and Noncitrullinated Epitopes in Rheumatoid Arthritis
Authors: Katherine P. Liao, Jeffrey A. Sparks, Boris P. Hejblum, I‐Hsin Kuo, Jing Cui, Lauren J. Lahey, Andrew Cagan, Vivian S. Gainer, Weidong Liu, T. Tony Cai, Jeremy Sokolove, Tianxi Cai
Journal: Arthritis & Rheumatology (2016)

Objective Patients with rheumatoid arthritis (RA) develop autoantibodies against a spectrum of antigens, but the clinical significance of these autoantibodies is unclear. Using a phenome‐wide association study (PheWAS) approach, we examined the association between autoantibodies and clinical subphenotypes of RA. Methods This study was conducted in a cohort of RA patients identified from the electronic medical records (EMRs) of 2 tertiary care centers. Using a published multiplex bead assay, we measured 36 autoantibodies targeting epitopes implicated in RA. We extracted all International Classification of Diseases, Ninth Revision (ICD‐9) codes for each subject and grouped them into disease categories (PheWAS codes), using a published method. We tested for the association of each autoantibody (grouped by the targeted protein) with PheWAS codes. To determine significant associations (at a false discovery rate [FDR] of ≤0.1), we reviewed the medical records of 50 patients with each PheWAS code to determine positive predictive values (PPVs). Results We studied 1,006 RA patients; the mean ± SD age of the patients was 61.0 ± 12.9 years, and 79.0% were female. A total of 3,568 unique ICD‐9 codes were grouped into 625 PheWAS codes; the 206 PheWAS codes with a prevalence of ≥3% were studied. Using the PheWAS method, we identified 24 significant associations of autoantibodies to epitopes at an FDR of ≤0.1. The associations that were strongest and had the highest PPV for the PheWAS code were autoantibodies against fibronectin and obesity ( P = 6.1 × 10 −4 , PPV 100%), and that between fibrinogen and pneumonopathy ( P = 2.7 × 10 −4 , PPV 96%). Pneumonopathy codes included diagnoses for cryptogenic organizing pneumonia and obliterative bronchiolitis. Conclusion We demonstrated application of a bioinformatics method, the PheWAS, to screen for the clinical significance of RA‐related autoantibodies. Using the PheWAS approach, we identified potentially significant links between variations in the levels of autoantibodies and comorbidities of interest in RA.
AB0361 Evaluation of Baseline Characteristics of Rheumatoid Arthritis Patients Treated with Abatacept or Tumor Necrosis Factor Inhibitors in Clinical Practice in Spain:
Authors: M.V. Hernández, C.A. Sánchez-Piedra, J.D. Cañete, F. Sánchez-Alonso, J. Manero-Ruiz, A. Ortiz-García, R. Rosello Pardo, E. Pérez-Pampín, C. Rodriguez-Lozano, R. Sanmarti, J.J. Gomez-Reino
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> Biological therapies have demonstrated efficacy in patients with rheumatoid arthritis (RA) improving the prognosis. The most widely used biological agents are tumor necrosis factor inhibitors (TNFi), although other biological agents with different mechanisms of actions, such abatacept, have been approved. Although all these drugs are indicated in RA, there is limited data on their use and whether differences in baseline characteristics of RA patients treated with different biologics <h3>Objectives</h3> To analyze differences in baseline characteristics of RA patients treated with abatacept, a T-cell co-stimulation inhibitor, compared with those treated with a TNFi <h3>Methods</h3> All BIOBADASER 2.0 register patients diagnosed with RA and treated with abatacept from January 2008 to December 2014 were selected. Baseline sociodemographic and clinical characteristics were analyzed compared them with RA patients treated with TNFi during the same period. Variables analyzed: age; gender; disease duration; positivity of rheumatoid factor; disease activity at initiation of biological measured by the DAS-28 score; number of previous biological agents (0, 1, ≥2); and concomitant glucocorticoid treatment. Differences between abatacept and TNFi patients in baseline DAS28 were analyzed according to the number of previous biological drugs received <h3>Results</h3> From January 2008 to December 2014, 252 RA patients treated with abatacept and 640 with TNFi were included in the BIOBADASER 2.0 register. Baseline characteristics are shown in Table1. At baseline, patients treated with abatacept were significantly younger; had a longer disease duration; had received a greater number of previous biologics; and had a higher DAS-28 (significant in patients who had received 1 previous biologic) than those treated with TNFi <h3>Conclusions</h3> Patients with RA treated with abatacept have more active disease and a poorer prognosis that those treated with TNFi, significantly longer disease duration, have failed more previous biological agents and have higher baseline inflammatory activity <h3>Disclosure of Interest</h3> None declared
SP0018 DNA Methylation and Osteoarthritis
Authors: L.N. Reynard
Journal: Annals of the Rheumatic Diseases (2016)

One mechanism of epigenetic gene regulation is DNA methylation, which involves the addition of a methyl group to a cytosine base by DNA methyltransferase enzymes and occurs predominantly at CpG dinucleotides in mammalian cells. DNA methylation within the gene promoter regions is associated with gene repression through effects on transcription factor binding and recruitment of chromatin remodelling complexes. In contrast, gene body methylation positively correlates with gene expression and has been implicated in transcription from alternative promoters as well as alternative splicing. DNA methylation changes occur during aging and in response to environmental factors including diet and smoking. Furthermore, aberrant DNA methylation patterns have been implicated in the aetiology of many common human disease including cancer, RA and SLE. Over the last 10 years, there has been increasing interest in the potential contribution of DNA methylation in the molecular mechanisms underlying OA pathogenesis, which will be the focus of this talk. I will begin by examining candidate gene studies that have focused on the relationship between cartilage promoter methylation, transcription factor binding and mRNA expression of genes implicated in OA, including the OA susceptibility gene <i>GDF5</i>, the chondrogenic transcription factor SOX9 and the matrix degrading enzyme MMP13. I will then review the key findings from genome-wide DNA methylation studies of osteoarthritic cartilage and bone. These DNA methylome studies have shown that hip and knee cartilage are epigenetically distinct, and have highlighted the potential importance of cartilage inflammation and TGFβ signalling in OA pathogenesis. I will finish by discussing areas for future DNA methylation studies in OA research and, given that OA is a disease of the whole joint, the potential to extend these analyses to other tissue compartments. <h3>Disclosure of Interest</h3> None declared
Biomaterial‐Based Implantable Devices for Cancer Therapy
Authors: Sue Anne Chew, Serena Danti
Journal: Advanced Healthcare Materials (2016)

This review article focuses on the current local therapies mediated by implanted macroscaled biomaterials available or proposed for fighting cancer and also highlights the upcoming research in this field. Several authoritative review articles have collected and discussed the state‐of‐the‐art as well as the advancements in using biomaterial‐based micro‐ and nano‐particle systems for drug delivery in cancer therapy. On the other hand, implantable biomaterial devices are emerging as highly versatile therapeutic platforms, which deserve an increased attention by the healthcare scientific community, as they are able to offer innovative, more effective and creative strategies against tumors. This review summarizes the current approaches which exploit biomaterial‐based devices as implantable tools for locally administrating drugs and describes their specific medical applications, which mainly target resected brain tumors or brain metastases for the inaccessibility of conventional chemotherapies. Moreover, a special focus in this review is given to innovative approaches, such as combined delivery therapies, as well as to alternative approaches, such as scaffolds for gene therapy, cancer immunotherapy and metastatic cell capture, the later as promising future trends in implantable biomaterials for cancer applications.
Genome-Wide Expression Profiling Predicts Treatment Outcome in Classical Hodgkin Lymphoma
Authors: Christian Steidl, Tang Lee, Sohrab P. Shah, Guangming Han, Tarun Nayar, Allen Delaney, Steven Jones, Wing C. Chan, Andreas Rosenwald, Lisa M. Rimsza, Elias Campo, Elaine S. Jaffe, Louis M. Staudt, Georg Lenz, Joseph M. Connors, Randy D. Gascoyne
Journal: Blood (2008)